Recent Updates
Recently added Catalysts
CBLL Positive Sentiment

Ceribell to Participate in the William Blair 46th Annual Growth Stock Conference

Key Takeaway: Ceribell, Inc. announced that its CEO, Dr. Jane Chao, will present at the William Blair 46th Annual Growth Stock Conference on June 3, 2026. The event will showcase Ceribell's innovative approach to diagnosing and managing serious neurological conditions through its FDA-cleared Ceribell System. A webcast of the presentation will be available on the company's website.
Price reaction · baseline $16.96 (2026-05-19 close) · hit after-hours · clean, no other CBLL news in the window
day 0 close
+6.7%
day 1
+10.5%
day 3 · peak
+10.8%

Market Sentiment Analysis

POSITIVE FACTORS

  • Ceribell's participation in a notable conference highlights its growth potential.
  • The Ceribell System is FDA-cleared, indicating regulatory approval and credibility.
  • The company's focus on serious neurological conditions addresses significant healthcare needs.

Full Press Release Details

SUNNYVALE, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, will present at the upcoming William Blair 46thAnnual Growth Stock Conference in Chicago. The presentation will take place on Wednesday, June 3, 2026, at 9:20 a.m. Pacific Daylight Time / 11:20 a.m. Central Daylight Time.

Event: William Blair 46thAnnual Growth Stock ConferenceDate: Wednesday, June 3, 2026Time: 9:20 a.m. PDT / 11:20 a.m. CDT

A live and archived webcast of the presentation will be available in the "Investor Relations" section of the Ceribell website athttps://investors.ceribell.com/.
About CeriBell, Inc.Ceribell is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. Ceribell has developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute-care setting. By combining proprietary, highly portable, and rapidly deployable hardware with sophisticated artificial intelligence (“AI”)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. The Ceribell System is FDA-cleared for detection of seizure and delirium in patients in intensive care units and emergency rooms across the U.S. Ceribell is headquartered in Sunnyvale, California. For more information, please visitwww.ceribell.comor follow the company onLinkedIn.

Investor ContactBrian JohnstonGilmartin GroupInvestors@ceribell.com

Media ContactBrian PricePress@ceribell.com

Frequently Asked Questions

When will Ceribell present at the conference?

Ceribell will present on June 3, 2026, at 9:20 a.m. PDT.

What is the focus of Ceribell's technology?

Ceribell focuses on diagnosing and managing serious neurological conditions.

Where can I watch the Ceribell presentation?

The presentation will be available via webcast on Ceribell's investor relations website.

What is the Ceribell System used for?

The Ceribell System is used for rapid diagnosis and monitoring of seizures and delirium.

Last updated: May 20, 2026